Joel Greenbowe

3.0k citations
20 papers · 1.1k · h-index 13

Impact in

  • Cancer Research top 5%
    • Cancer Genomics and Diagnostics
  • Oncology top 5%
    • Pancreatic and Hepatic Oncology Research
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies

Papers in

  • Oncology 11
    • Cancer Immunotherapy and Biomarkers 4
    • Pancreatic and Hepatic Oncology Research 3
    • Lung Cancer Research Studies 2
    • CAR-T cell therapy research 2
    • Colorectal Cancer Treatments and Studies 2
  • Pulmonary and Respiratory Medicine 9
    • Lung Cancer Treatments and Mutations 9
Co-authors
Jeffrey S. Ross (11 shared papers)Siraj M. Ali (17 shared papers)Vincent A. Miller (16 shared papers)Samuel J. Klempner (5 shared papers)Alexa B. Schrock (7 shared papers)Sai‐Hong Ignatius Ou (3 shared papers)Kyle Gowen (3 shared papers)Phil Stephens (4 shared papers)
Journals
Journal of Clinical Oncology (4 papers)Cancer Research (2 papers)Lung Cancer (2 papers)Clinical Cancer Research (1 paper)PLoS ONE (1 paper)
Partner nations
United StatesSouth KoreaChina

In The Last Decade

Joel Greenbowe

18 papers receiving 1.1k citations

Peers

Joel Greenbowe
Comparison fields: 5 of 52
  • Cancer Research 410
  • Oncology 690
  • Pulmonary and Respiratory Medicine 480
  • Pathology and Forensic Medicine 200
  • Molecular Biology 290
Replace Kyle Gowen with:
Kyle Gowen United States
Zishuo I. Hu United States
Siddhartha Devarakonda United States
Nicolas Pécuchet France
Paola Bordi Italy
Daygen L. Finch Canada
Angela N. Bartley United States
Hyunjae R. Kim United States
Tingsheng Peng China
Bethany Pitcher Canada
Joel Greenbowe relative to Kyle Gowen United States Kyle Gowen's profile →
Citations per field
00.5×2×2.6×
Kyle Gowen · 1×
Citations per year

Countries citing papers authored by Joel Greenbowe

Since Specialization
Citations

This map shows the geographic impact of Joel Greenbowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Greenbowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Greenbowe more than expected).

Fields of papers citing papers by Joel Greenbowe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Greenbowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Greenbowe. The network helps show where Joel Greenbowe may publish in the future.

Co-authors

The 25 scholars most cited alongside Joel Greenbowe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joel Greenbowe Line = papers co-authored together Joel Greenbowe links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
Gastroenterology ·Aatur D. Singhi, Ben George, Joel Greenbowe, Jon Chung, James Suh, Anirban Maitra, Samuel J. Klempner, Andrew Hendifar, Javle Milind, Talia Golan, Randall E. Brand, Amer H. Zureikat, Somak Roy, Alexa B. Schrock, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Nathan Bahary
2019227
2
Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Clinical Cancer Research ·Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi
2015203
3
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
Journal of Gastrointestinal Oncology ·David Fabrizio, Thomas J. George, Richard F. Dunne, Garrett M. Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B. Schrock, Aram F. Hezel, Jeffrey S. Ross, P. J. Stephens, Siraj M. Ali, Vincent A. Miller, Marwan Fakih, Samuel J. Klempner
2018201
4
Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
Journal of the National Comprehensive Cancer Network ·Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh T. Nguyen, Jamie Koo, Jon Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil K. Dasyam, Nathan Bahary
201774
5
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI
Lung Cancer ·Samuel J. Klempner, Lyudmila Bazhenova, Fadi S. Braiteh, Petros Nikolinakos, Kyle Gowen, Claudia M. Cervantes, Juliann Chmielecki, Joel Greenbowe, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller, Siraj M. Ali, Sai‐Hong Ignatius Ou
201572
6
Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib
Journal of Thoracic Oncology ·Sai‐Hong Ignatius Ou, Samuel J. Klempner, Joel Greenbowe, Michele C. Azada, Alexa B. Schrock, Siraj M. Ali, Jeffrey S. Ross, Philip J. Stephens, Vincent A. Miller
201471
7
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
Oncogene ·Hyo Song Kim, Minkyu Jung, Hari Kang, H Kim, C. W. Park, S-M Kim, Sang Joon Shin, Se Hoon Kim, S G Kim, Eun‐Kyung Kim, Mi Ran Yun, Zhihuang Zheng, Kee Yang Chung, Joel Greenbowe, Siraj M. Ali, (unknown), Byoung Chul Cho
201768
8
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
Lung Cancer ·Sai‐Hong Ignatius Ou, Joel Greenbowe, Ziad U. Khan, Michele C. Azada, Jeffrey S. Ross, Phil J. Stevens, Siraj M. Ali, Vincent A. Miller, Barbara J. Gitlitz
201561
9
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
Oncotarget ·Sun Min Lim, Eun Young Kim, Hye Ryun Kim, Siraj M. Ali, Joel Greenbowe, Hyo Sup Shim, Hyun Chang, Seungtaek Lim, Soonmyung Paik, Byoung Chul Cho
201637
10
Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type
Gynecologic Oncology ·Douglas I. Lin, Yakov Chudnovsky, Bridget Duggan, Deborah A. Zajchowski, Joel Greenbowe, Jeffrey S. Ross, Laurie M. Gay, Siraj M. Ali, Julia A. Elvin
201736
11
Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.
Journal of Clinical Oncology ·Thomas J. George, Garrett M. Frampton, James Sun, Kyle Gowen, Mark Kennedy, Joel Greenbowe, Alexa B. Schrock, Siraj M. Ali, Samuel J. Klempner, Aram F. Hezel, Jeffrey S. Ross, Phil Stephens, Vincent A. Miller, David Fabrizio
201626
12
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
PLoS ONE ·Michael E. Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace Akerley, Afshin Dowlati, Ben Creelan, J. Kevin Hicks, Paul J. Hesketh, Karen Kelly, Jonathan W. Riess, Vincent A. Miller, Philip J. Stephens, Garrett M. Frampton, Siraj M. Ali, Jeffrey P. Gregg, Lee A. Albacker
201816
13
Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.
Journal of Clinical Oncology ·Douglas B. Johnson, Garrett M. Frampton, Matthew J. Rioth, Erik Yusko, Riley Ennis, David Fabrizio, Joel Greenbowe, Siraj M. Ali, Dennie T. Frederick, Igor Puzanov, Justin M. Balko, Justin Cates, Jeffrey S. Ross, Harlan Robins, Vincent A. Miller, Phil Stephens, Ryan J. Sullivan, Jeffrey A. Sosman, Christine M. Lovly
201612
14
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma
Clinical Lung Cancer ·David M. DiBardino, Anjali Saqi, Julia A. Elvin, Joel Greenbowe, James Suh, Vincent A. Miller, Siraj M. Ali, Mark Stoopler, William A. Bulman
201612
15
Abstract 1118: Activation of MET via diverse exon 14 skipping mutations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
Cancer Research ·Garrett M. Frampton, Siraj M. Ali, Juliann Chmielecki, Mark R. Rosenzweig, Timothy Brennan, Zachary R. Chalmers, Julia A. Elvin, Alex Fichtenholtz, Kyle Gowan, Joel Greenbowe, Adrienne Johnson, Lily Khaira, Doron Lipson, Caitlin McMahon, Steven Roels, Roman Yelensky, Deborah Morosini, Philip Stephens, Vincent A. Miller
20158
16
Abstract 2987: Validation and clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB)
Cancer Research ·Daniel S. Lieber, Mark Kennedy, Douglas B. Johnson, Jonathan E. Rosenberg, Marcin Kowanetz, Joel Greenbowe, Garrett M. Frampton, Caitlin Connelly, Alexa B. Schrock, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Vincent A. Miller, David Fabrizio
20173
17
Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology ·Aatur D. Singhi, Joel Greenbowe, Jon Chung, Andrew Hendifar, Nathan Bahary, Alexa B. Schrock, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Siraj M. Ali, Ben George
20181
18
Abstract B16: Validation and clinical feasibility of a Foundation Medicine assay to identify immunotherapy response potential through tumor mutational burden (TMB)
Cancer Immunology Research ·Daniel S. Lieber, Mark Kennedy, Douglas B. Johnson, Joel Greenbowe, Garrett M. Frampton, Alexa B. Schrock, Jeffrey S. Ross, P. J. Stephens, Siraj M. Ali, Vincent A. Miller, David Fabrizio
20171
19
Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history.
Journal of Clinical Oncology ·Alexander Drilon, Lu Wang, Maria E. Arcila, Eun‐Jung Cho, Sohail Balasubramanian, Joel Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi
20141
20
Integrated Genetic Profiling Of JAK2 Wildtype Chronic-Phase Myeloproliferative Neoplasms
Blood ·Raajit K. Rampal, Sean M. Devlin, Jay P. Patel, Kristina M. Knapp, Minal Patel, Joel Greenbowe, Lauren Young, Jie He, Kai Wang, Michelle Nahas, Roman Yelensky, Geoff Otto, Doron Lipson, Philip J. Stephens, Vincent A. Miller, Ross L. Levine
20130

About Joel Greenbowe

Joel Greenbowe is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Surgery, having authored 20 papers that have together received 1.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (7 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Lung Cancer Research Studies (2 papers), Cancer therapeutics and mechanisms (2 papers), CAR-T cell therapy research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Cancer Research (410 citations), Oncology (690 citations), Pulmonary and Respiratory Medicine (480 citations), Pathology and Forensic Medicine (200 citations) and Molecular Biology (290 citations). Joel Greenbowe has collaborated with scholars based in United States, South Korea and China. Frequent co-authors include Jeffrey S. Ross, Siraj M. Ali, Vincent A. Miller, Samuel J. Klempner, Alexa B. Schrock, Sai‐Hong Ignatius Ou, Kyle Gowen, Phil Stephens, Jon Chung and Aatur D. Singhi. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Lung Cancer, Clinical Cancer Research and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kyle GowenBreakdown of academic impact, for papers by Zishuo I. HuBreakdown of academic impact, for papers by Siddhartha DevarakondaBreakdown of academic impact, for papers by Nicolas PécuchetBreakdown of academic impact, for papers by Paola BordiBreakdown of academic impact, for papers by Daygen L. FinchBreakdown of academic impact, for papers by Angela N. BartleyBreakdown of academic impact, for papers by Hyunjae R. KimBreakdown of academic impact, for papers by Tingsheng PengBreakdown of academic impact, for papers by Bethany Pitcher